PriceTargets.com logo

Innoviva - INVA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.00
  • Forecasted Upside: 2.85%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.64 As of 02/7/2023 01:00 AM ET
▼ -0.07 (-0.55%)

This chart shows the closing price for INVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Innoviva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INVA

Analyst Price Target is $13.00
▲ +2.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Innoviva in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 2.85% upside from the last price of $12.64.

This chart shows the closing price for INVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Innoviva. This rating has held steady since July 2022, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyLower TargetUnderweight$14.00 ➝ $13.00Low
10/13/2022Morgan StanleyBoost TargetUnderweight$13.00 ➝ $14.00Low
7/20/2022The Goldman Sachs GroupInitiated CoverageNeutralLow
4/12/2022Morgan StanleyBoost TargetUnderweight$12.00 ➝ $13.00Low
2/23/2022Morgan StanleyBoost TargetUnderweight$10.00 ➝ $12.00Low
11/11/2020Morgan StanleyBoost TargetUnderweight$8.00 ➝ $10.00Medium
6/25/2018Stifel NicolausReiterated RatingHold ➝ Hold$16.00High
4/27/2018Stifel NicolausLower TargetHold ➝ Hold$17.00 ➝ $16.00Medium
4/19/2018Berenberg BankInitiated CoverageBuyLow
2/9/2018Stifel NicolausReiterated RatingHold$17.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.49 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 2 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 6 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Innoviva logo
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: $12.64
Low: $12.44
High: $12.69

50 Day Range

MA: $13.08
Low: $12.42
High: $13.64

52 Week Range

Now: $12.64
Low: $11.56
High: $20.71

Volume

774,992 shs

Average Volume

642,344 shs

Market Capitalization

$882.02 million

P/E Ratio

3.96

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Innoviva?

The following sell-side analysts have issued reports on Innoviva in the last twelve months: Morgan Stanley, StockNews.com, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for INVA.

What is the current price target for Innoviva?

1 Wall Street analysts have set twelve-month price targets for Innoviva in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 2.8%. Morgan Stanley has the highest price target set, predicting INVA will reach $13.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $13.00 for Innoviva in the next year.
View the latest price targets for INVA.

What is the current consensus analyst rating for Innoviva?

Innoviva currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INVA, but not buy more shares or sell existing shares.
View the latest ratings for INVA.

What other companies compete with Innoviva?

Other companies that are similar to Innoviva include Intercept Pharmaceuticals, ImmunoGen, OPKO Health, Emergent BioSolutions and Ligand Pharmaceuticals. Learn More about companies similar to Innoviva.

How do I contact Innoviva's investor relations team?

Innoviva's physical mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company's listed phone number is (650) 238-9600 and its investor relations email address is [email protected] The official website for Innoviva is www.inva.com. Learn More about contacing Innoviva investor relations.